Sign In
Buy NVS
$153.38
+4.45 (+2.99%)
At Close: Jun 23, 2026
4 High-Yield Dividend Aristocrat Retirement Dream Stocks
05:30pm, Saturday, 02'nd Jul 2022 Seeking Alpha
This bear market has brought the worst first half for stocks since 1970. Click here for my list of 4 high-yield, low volatility aristocrats.
FDA and drug makers deepen their commitment to clinical-trial diversity. Will it work?
04:34pm, Saturday, 02'nd Jul 2022 MarketWatch
After years of ‘lackluster’ efforts, regulators and companies are finally aligned in their goal to make clinical trials more representative of U.S. population.
4 High-Yield Dividend Aristocrat Retirement Dream Stocks
01:30pm, Saturday, 02'nd Jul 2022
This bear market has brought the worst first half for stocks since 1970. Market timing is proven to be the absolute worst strategy you can try, a 98% guaranteed road to underperformance or even financ
Novartis (NVS) Announces Positive Data on Oncology Drug
03:01pm, Friday, 01'st Jul 2022 Zacks Investment Research
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
Novartis (NVS) Announces Positive Data on Oncology Drug
12:18pm, Friday, 01'st Jul 2022
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
10:57am, Friday, 01'st Jul 2022 Zacks Investment Research
Sanofi, Merck, Novartis, Pfizer and J&J are part of Zacks top Analyst Blog.
2 Healthcare Stocks That Could Help Set You Up for Life
03:07pm, Thursday, 30'th Jun 2022 The Motley Fool
These stocks could create significant wealth for shareholders in the long run.
2 Healthcare Stocks You Can Buy and Hold for the Next Decade
02:53pm, Thursday, 30'th Jun 2022 The Motley Fool
The U.S. economy could soon be heading into a recession.
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
12:46pm, Thursday, 30'th Jun 2022 Zacks Investment Research
An FDA panel recommends updating COVID-19 booster shots. EU approvals for Sanofi's (SNY) two new drugs and expanded use of Merck's (MRK) Keytruda and Novartis' (NVS) Cosentyx.
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
02:28pm, Wednesday, 29'th Jun 2022 Zacks Investment Research
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Novartis to axe 8,000 jobs, some will be transferred to India
07:42am, Wednesday, 29'th Jun 2022
Novartis AG (ADR) (NYSE:NVS) is planning to cut 8,000 jobs or more than 7% of the pharma giant's global workforce as part of a large restructuring programme. Some of the jobs will be transferred to
Novartis Will Cut Up to 8,000 Jobs Under CEO's Shake-Up Plan
03:39pm, Tuesday, 28'th Jun 2022
The pharmaceutical giant said about 1,400 roles in its Switzerland headquarters could be eliminated due to a restructuring plan.
Novartis plans to cut up to 1,400 jobs in Switzerland - TagesAnzeiger
11:17am, Tuesday, 28'th Jun 2022
Swiss pharmaceutical group Novartis informed staff on Tuesday it plans to lay off more than one in 10 employees in Switzerland, the TagesAnzeiger newspaper reported in its online edition.
Why Inovio Pharmaceuticals Stock Topped the Market on Monday
11:10pm, Monday, 27'th Jun 2022 The Motley Fool
The appointment of a new top executive clearly meets with investor approval.
Q2 Earnings Season Preview and Featured Analyst Reports for J&J, AMD & Union Pacific
04:55pm, Monday, 27'th Jun 2022 Zacks Investment Research
Today's Research Daily features preview of the Q2 earnings season and new research reports for J&J (JNJ), AMD (AMD), and Union Pacific (UNP).
